Article
Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.
Neuro-oncology - 1 Mar 2026
Arakawa Yoshiki, Saito Ryuta, Kanemura Yonehiro, Mishima Kazuhiko, Koriyama Shunichi, Narita Yoshitaka, Kumabe Toshihiro, Motomura Kazuya, Sugiyama Kazuhiko, Yamasaki Fumiyuki, Mukasa Akitake, Kanamori Masayuki, Kuga Daisuke, Nagane Motoo, Kakurai Yasuyuki, Isobe Koji, Nakamura Hideo
Abstract excerpt
BACKGROUND: Gliomas are primary brain tumors arising from glial cells. WHO grade 2 gliomas are initially managed with surgery for diagnosis and tumor reduction. However, complete resection is difficult due to their infiltrative growth into the normal brain and the need to preserve brain function. Current treatment options for WHO grade 2 gliomas are limited. Isocitrate dehydrogenase 1 (IDH1) mutations are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.